(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 August 2020 (13.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/163620 A1

(51) International Patent Classification:
A61K 31/4196 (2006.01) *A61K 47/40* (2006.01)
A61K 31/5415 (2006.01) *A61P 25/06* (2006.01)
A61K 47/02 (2006.01)

(21) International Application Number:
PCT/US2020/017046

(22) International Filing Date:
06 February 2020 (06.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/802,198	06 February 2019 (06.02.2019)	US
62/803,756	11 February 2019 (11.02.2019)	US
62/835,613	18 April 2019 (18.04.2019)	US
62/846,311	10 May 2019 (10.05.2019)	US
62/860,705	12 June 2019 (12.06.2019)	US
62/895,933	04 September 2019 (04.09.2019)	US
62/895,956	04 September 2019 (04.09.2019)	US
62/955,905	31 December 2019 (31.12.2019)	US

(71) Applicant: **AXSOME THERAPEUTICS, INC.** [US/US]; 200 Broadway, 3rd Floor, New York, NY 10038 (US).


(72) Inventor: **TABUTEAU, Herriot**; 200 Broadway, 3rd Floor, New York, NY 10038 (US).

(74) Agent: **JOHNSON, Brent A.** et al.; Maschoff Brennan, 100 Spectrum Center Drive, Suite 1200, Irvine, California 92618 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

FIG. 14



(57) Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

WO 2020/163620 A1

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*